Market Place
Sourcing Support
All News #Library
Biotech
Beyond Rezdiffra: The 4 Most Promising MASH Pipelines In Play
23 Feb 2026 //
BIOSPACE
Madrigal Reports Q4 and Full-Year 2025 Financial Results
19 Feb 2026 //
GLOBENEWSWIRE
Madrigal Embraces Novo Competition As MASH Drug Gains Steam
19 Feb 2026 //
FIERCE PHARMA
Madrigal Pharma Announces Inducements Under Nasdaq Rule
17 Feb 2026 //
GLOBENEWSWIRE
Madrigal Pens $4.4B Deal For siRNA Drugs In Fresh Rezdiffra Play
12 Feb 2026 //
FIERCE BIOTECH
Madrigal Pharma Awards Inducement Grants Per Nasdaq LR 5635(C)(4)
05 Feb 2026 //
GLOBENEWSWIRE
Madrigal Pharma Grants Inducement Under Nasdaq Rule 5635(c)(4)
21 Jan 2026 //
GLOBENEWSWIRE
Madrigal Expands MASH Pipeline With Ervogastat Phase 2 Agreement
09 Jan 2026 //
GLOBENEWSWIRE
Galmed Secures Patents for Aramchol, Rezdiffra
04 Dec 2025 //
PR NEWSWIRE
Madrigal Pharma Grants Inducements Under Nasdaq Listing Rule
04 Dec 2025 //
GLOBENEWSWIRE
Madrigal Pharma Awards Inducement Grants Per Nasdaq LR 5635(C)(4)
20 Nov 2025 //
GLOBENEWSWIRE
Madrigal Shows Rezdiffra Boosts Imaging And Biomarkers
10 Nov 2025 //
GLOBENEWSWIRE
Madrigal To Unveil Latest MASH Program Data At AASLD Meeting
28 Oct 2025 //
GLOBENEWSWIRE
Madrigal Pharma Grants Inducement Awards Under Nasdaq LR
07 Oct 2025 //
GLOBENEWSWIRE
Madrigal Pharmaceuticals Grants Inducement Awards under Nasdaq
07 Aug 2025 //
GLOBENEWSWIRE
Madrigal Makes Potential $2B+ Bet for CSPC`s GLP-1 Pill
31 Jul 2025 //
BIOSPACE
Lilly pads tirzepatide`s MASH win with detailed fibrosis data
06 Jun 2024 //
FIERCE PHARMA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.